The fibroblast as a therapeutic target in rheumatoid arthritis.

[1]  M. Genovese,et al.  Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. , 2013, Arthritis and rheumatism.

[2]  J. Dean,et al.  The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look , 2012, The open rheumatology journal.

[3]  D. Scott.  Biologics‐Based Therapy for the Treatment of Rheumatoid Arthritis , 2012, Clinical pharmacology and therapeutics.

[4]  Georg Schett,et al.  The pathogenesis of rheumatoid arthritis. , 2011, The New England journal of medicine.

[5]  G. Firestein,et al.  The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon , 2011, Annals of the rheumatic diseases.

[6]  B. Nair,et al.  Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells , 2011, Breast Cancer Research.

[7]  S. Gay,et al.  A BAFF/APRIL-dependent TLR3-stimulated pathway enhances the capacity of rheumatoid synovial fibroblasts to induce AID expression and Ig class-switching in B cells , 2011, Annals of the rheumatic diseases.

[8]  P. Tak,et al.  DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts , 2011, Genes and Immunity.

[9]  P. Tak,et al.  Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? , 2011, Autoimmunity reviews.

[10]  P. Tak,et al.  Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis , 2011, PloS one.

[11]  C. Buckley.  Why does chronic inflammation persist: An unexpected role for fibroblasts. , 2011, Immunology letters.

[12]  N. Karlsson,et al.  The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis , 2011, Arthritis Research & Therapy.

[13]  J. Tavernier,et al.  CD248 and its cytoplasmic domain: a therapeutic target for arthritis. , 2010, Arthritis and rheumatism.

[14]  James O. Jones,et al.  Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .

[15]  A. Filer,et al.  Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium , 2010, Immunology.

[16]  M. Esteller,et al.  Epigenetic modifications and human disease , 2010, Nature Biotechnology.

[17]  M. Hochberg,et al.  Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. , 2010, Seminars in arthritis and rheumatism.

[18]  R. Gay,et al.  Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. , 2010, Arthritis and rheumatism.

[19]  P. Tak,et al.  Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. , 2010, Arthritis and rheumatism.

[20]  G. Herbein,et al.  Targeting intracellular signaling pathways to treat rheumatoid arthritis: Pandora's box? , 2010, Joint, bone, spine : revue du rhumatisme.

[21]  R. Gay,et al.  DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. , 2009, Arthritis and rheumatism.

[22]  P. Robbins,et al.  Synovial fibroblasts spread rheumatoid arthritis to unaffected joints , 2009, Nature Medicine.

[23]  M. Kawai,et al.  Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway , 2009, Modern rheumatology.

[24]  J. Smolen,et al.  Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. , 2009, Arthritis and rheumatism.

[25]  R. Kalluri,et al.  Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.

[26]  G. Burmester,et al.  Is tocilizumab in combination with traditional DMARDs safe and effective for patients with active RA? , 2009, Nature Clinical Practice Rheumatology.

[27]  H. Pavenstädt,et al.  Cell death in rheumatoid arthritis , 2009, Apoptosis.

[28]  Stephen Kelly,et al.  Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium , 2009, PLoS medicine.

[29]  C. Buckley,et al.  Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. , 2008, Arthritis and rheumatism.

[30]  R. Gay,et al.  Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. , 2007, Arthritis and rheumatism.

[31]  M. Takeichi,et al.  Cadherin-11 in Synovial Lining Formation and Pathology in Arthritis , 2007, Science.

[32]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[33]  U. Müller-Ladner,et al.  Microarrays demystified. , 2004, Environmental health perspectives.

[34]  F. M. Thomas,et al.  Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. , 2006, The Journal of clinical investigation.

[35]  Howard Y. Chang,et al.  Anatomic Demarcation by Positional Variation in Fibroblast Gene Expression Programs , 2006, PLoS genetics.

[36]  J. Lord,et al.  Differential survival of leukocyte subsets mediated by synovial, bone marrow, and skin fibroblasts: site-specific versus activation-dependent survival of T cells and neutrophils. , 2006, Arthritis and rheumatism.

[37]  G. Christofori,et al.  Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. , 2006, Cancer cell.

[38]  C. Isacke,et al.  Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium , 2005, FEBS letters.

[39]  B. Bresnihan,et al.  Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis , 2005, European journal of immunology.

[40]  D. Patel,et al.  Cadherin-11 Provides Specific Cellular Adhesion between Fibroblast-like Synoviocytes , 2004, The Journal of experimental medicine.

[41]  A. Otaka,et al.  Identification of a CXCR4 antagonist, a T140 analog, as an anti‐rheumatoid arthritis agent , 2004, FEBS letters.

[42]  K. Preissner,et al.  Human Thy-1 (CD90) on Activated Endothelial Cells Is a Counterreceptor for the Leukocyte Integrin Mac-1 (CD11b/CD18)1 , 2004, The Journal of Immunology.

[43]  N. Miyasaka,et al.  Gene Transfer of a Cell Cycle Modulator Exerts Anti-Inflammatory Effects in the Treatment of Arthritis 1 , 2003, The Journal of Immunology.

[44]  G. Haines,et al.  IL-6 and Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts1 , 2003, The Journal of Immunology.

[45]  Dominique Schols,et al.  AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-γ Receptor-Deficient Mice1 , 2001, The Journal of Immunology.

[46]  W. O'Fallon,et al.  Lymphoid Neogenesis in Rheumatoid Synovitis1 , 2001, The Journal of Immunology.

[47]  J. Lord,et al.  Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. , 2001, Trends in immunology.

[48]  T. Kipps,et al.  Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism. , 2001, The Journal of clinical investigation.

[49]  R. Gay,et al.  Expression of osteoclast differentiation factor in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[50]  J. Lord,et al.  Persistent Induction of the Chemokine Receptor CXCR4 by TGF-β1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium1 , 2000, The Journal of Immunology.

[51]  J. Kriegsmann,et al.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. , 1996, The American journal of pathology.

[52]  M. Burdick,et al.  Growth-related gene product alpha. A chemotactic cytokine for neutrophils in rheumatoid arthritis. , 1995, Journal of immunology.

[53]  M. Burdick,et al.  Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. , 1994, The Journal of clinical investigation.

[54]  R. Strieter,et al.  Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. , 1991, Journal of immunology.

[55]  A. Kraneveld,et al.  Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. , 2012, Pharmacology & therapeutics.

[56]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[57]  D. Haskard,et al.  Expression of vascular cell adhesion molecule-1 in normal and inflamed synovium. , 1993, Laboratory investigation; a journal of technical methods and pathology.